SPRB

Business Context and Reporting Period

Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Spruce is a late-stage biopharmaceutical company focused on developing therapies for neurological disorders. Its primary asset is tralesinidase alfa enzyme replacement therapy ("TA-ERT") for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB). The company has no approved products and has not generated product revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Financing Activities: The company significantly increased its liquidity through a $64.4 million net proceeds underwritten public offering in April 2026 and a $15.0 million term loan (Tranche 1) from Avenue Capital Management in January 2026. Net cash provided by financing activities was $78.4 million for the six months ended June 30, 2026, compared to a net use of $0.8 million in the prior year period.
• Operating Expenses: Total operating expenses increased by $11.3 million (66%) year-over-year. R&D expenses rose by $9.3 million, primarily driven by increased clinical development and manufacturing costs for TA-ERT. G&A expenses increased by $2.0 million due to higher personnel and professional fees.
• Debt Structure: The company entered into a new loan agreement with Avenue Capital Management, creating a debt obligation of up to $50.0 million contingent on regulatory milestones. As of June 30, 2026, $15.0 million was outstanding.
• Stock Structure: The company completed a 1-for-75 reverse stock split in August 2025. All share and per-share data in the filing have been retroactively adjusted to reflect this split.

Guidance, Outlook, and Risks

• Regulatory Outlook: Management intends to submit a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026, seeking accelerated approval based on existing clinical data. A confirmatory Phase 3 trial is expected to initiate in Q4 2026.
• Liquidity: As of June 30, 2026, the company held $96.3 million in cash. Management believes this, combined with $5.5 million in proceeds from a private placement in August 2026, is sufficient to fund operations and debt obligations for at least 12 months.
• Capital Needs: The company anticipates continuing to incur significant net losses and will require substantial additional financing to complete clinical development, seek regulatory approval, and commercialize TA-ERT.
• Key Risks:
  • Financing Risk: Failure to secure additional capital could force delays or elimination of product development programs.
  • Regulatory Risk: Uncertainty regarding FDA acceptance of CSF HS-NRE as a surrogate endpoint for accelerated approval.
  • Debt Covenants: The Avenue Loan Agreement restricts additional indebtedness, liens, and dividends, and is secured by substantially all company assets, including intellectual property.
  • Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trial conduct.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $96.3 million cash balance plus the $5.5 million August 2026 private placement to fund the anticipated Q4 2026 BLA submission and confirmatory trial initiation.
• Debt Milestones: Monitor the achievement of regulatory milestones required to unlock Tranche 2 ($10M) and Tranche 3 ($15M) of the Avenue Loan.
• BLA Submission Timeline: Confirm the company's ability to meet the Q4 2026 target for the TA-ERT BLA submission and the FDA's acceptance of the proposed surrogate endpoint.
• Dilution: Assess the impact of the April 2026 public offering and potential future equity issuances under the $300 million Shelf Registration on existing shareholders.
• Manufacturing Capacity: Evaluate the readiness of third-party manufacturers to scale production for commercial launch if approval is received in mid-2027.